Compare GE Aerospace (GE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Heron Therapeutics Inc — how do they compare? GE Aerospace trades at $307.73 (market cap $315.02B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: GE Aerospace is far larger — about 4254.7× Heron Therapeutics Inc's market cap, and GE Aerospace pays a 0.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Heron Therapeutics Inc for 35 Days on average.
| GE | HRTX | |
|---|---|---|
Market Cap | $315.02B | $74.04M |
Volume | 3,800,907 | 3,668,095 |
Sector | Industrials | Health |
52-Week High | $381.22 | $1.49 |
52-Week Low | $273.25 | $0.27 |
Typical Hold Time | 111 Days | 35 Days |
Enterprise Value | $324.84B | $180.78M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $305.62, down 1.22% amid broader market weakness, with technical indicators showing bearish momentum below key moving averages. Fundamentally, the company demonstrates strong profitability with 17.72% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights the strategic $12 billion CPP acquisition to address supply chain constraints while maintaining robust shareholder returns through dividends and buybacks.
The outlook remains constructive given strong defense demand and operational execution, but high valuation and acquisition integration risks warrant caution. Analyst consensus is strongly bullish with a $409.60 price target representing 34% upside, though near-term technical pressure may persist until the Q3 earnings report provides clearer direction.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
